Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review - Top-Institutions - MDSpire

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

By
Xin Shen
Jiangnan Yang
Yang Du
Deyuan Fu
June 4, 2026
0 min

Frontiers In Immunology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

The University of Texas MD Anderson Cancer Center

Houston, Texas
Key Differentiators
- Oncology
- Breast Cancer
#2

Memorial Sloan Kettering Cancer Center

New York, New York
Key Differentiators
- Oncology
- Breast Cancer
#3

Dana-Farber Cancer Institute

Boston, Massachusetts
Key Differentiators
- Oncology
- Breast Cancer
#4

Barts Cancer Institute, Queen Mary University of London

London, England
Key Differentiators
- Oncology
#5

European Institute of Oncology

Milan, Italy
Key Differentiators
- Oncology

Original Source(s)

Frontiers In Immunology

Adjuvant chemotherapy combined with pembrolizumab immunotherapy for primary triple-negative neuroendocrine carcinoma of the breast: a case report and literature review

by Xin Shen, Jiangnan Yang, Yang Du, Deyuan Fu
June 4, 2026

Related Content

Blood Cancer Journal

Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis

Frontiers In Immunology

Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination

Frontiers In Medicine

Automated bone marrow cell classification using ensemble learning: performance, generalization, and clinical interpretability